TNF-α downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 284, Issue 1 53-1, 2003, Pages

  Menon, Chandrakala ^a   Iyer, Malini ^a   Prabakaran, Indira ^a   Canter, Robert J ^a   Lehr, Shannon C ^a   Fraker, Douglas L ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiangiogenic therapy; Antitumor therapy; Antivascular therapy; Vascular endothelial growth factor receptor

Indexed keywords

COMPLEMENTARY RNA; CYTOKINE RECEPTOR; DNA; FETAL LIVER KINASE 1; MELPHALAN; MESSENGER RNA; PROTEIN KINASE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; DOWN REGULATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS LIVER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MELANOMA; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

EID: 0037235099     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00971.2001     Document Type: Article

References (34)

1. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, and Smith LEH. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92: 10457-10461, 1995.
2. Alexander HR, Bartlet DL, Libutti SK, Fraker DL, Moser T, and Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16: 1479-1489, 1998.
3. Brekken RA, Overhosler JP, Stastny VA, Waltenberger J, Minna JD, and Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60: 5117-5124, 2000.
4. Brennan MF, Casper ES, and Harrison LB. Soft tissue sarcoma. In: Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott-Raven, 1997, p. 1738-1788.
5. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666-3670, 1975.
6. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van De Water L, and Senger DR. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 174: 1275-1278, 1991.
7. Eggermont AM, Koops HS, Klausner JM, Kroon BBR, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, and Lejeune FJ. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg 244: 756-765, 1996.
8. Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S, Beran M, Kantarjian HM, Freireich EJ, and Albitar M. High levels of VEGF receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 7: 795-799, 2000.
9. Fraker DL. Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 36: 841-908, 1999.
10. Fraker DL. Hyperthermic regional perfusion for melanoma of the limbs. Cutaneous Melanoma (3rd Ed.). St. Louis, MO: Quality Medical Publishing, 1998, p. 281-300.
11. Fraker DL, Alexander HR, Bartlett DL, and Rosenberg SA. A prospective randomized trial of therapeutic isolated limb perfusion (ILP) comparing melphalan (M) versus melphalan, tumor necrosis factor (TNF), and interferon-gamma (IFN): An initial report (Abstract). Soc Surg Oncol 49: 6, 1996.
12. Fraker DL and Coit D. Isolated perfusion of extremity tumors. Regional Therapy of Advanced Cancer. Philadelphia, PA: Lippincott-Raven, 1997, p. 333-349.
13. Fraker DL, Alexander HR, Ross M, Tyler D, Bartlett D, and Bauer T. A phase II trial of isolated limb perfusion with high dose tumor necrosis factor and melphalan for unresectable extremity sarcomas (Abstract). SSO Cancer Symp 52: 22, 1999.
14. Frater-Schroder M, Risau W, Hallmann R, and Gautschi P. Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 84: 5277-5281, 1987.
15. Goede V, Schmide T, Kimmina S, Kozian D, and Augustin, HG. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 78: 1385-1394, 1998.
16. Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, Meller I, and Klausner JM. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 79: 1129-1137, 1997.
17. Kamiyama M, Ichikawa y Ishikawa T, Chishima T, Hasegawa S, Hamaguchi Y, Nagashima Y, Miyagi Y, Mitsuhashi M, Hyndman D, Hoffman RM, Ohki S, and Shimada H. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther 9: 197-201, 2002.
18. Leinard D, Lejeune F, Delmotte J. High doses of TNF in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60, 1992.
19. Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, and Simons M. VEGF, Flk-1, and Flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol Heart Circ Physiol 270: H1803-H1811, 1996.
20. Lienard D, Lejeune F, and Ewalenko I. In transit metastases of malignant melanoma treated by high dose TNF in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 16: 234-240, 1992.
21. Millauer B, Longhi MP, Sawyer LK, Risau W, Ullrich A, and Strawn LM. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56: 1615-1620, 1996.
22. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, and Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846, 1993.
23. Nooijen PT, Eggermont AM, Schalkwijk L, Henzen-Logmans S, de Waal RM, and Ruiter DJ. Complete response of melanoma in transit metastases after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: A clinical and histopathological study of the delayed-type reaction pattern. Cancer Res 58: 4880-4887, 1998.
24. Olerichs RB, Hugh RH, Bernard O, Ziemiecki A, and Wilks AF. NYK/Flk-1: A putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo. Oncogene 8: 11-18, 1993.
25. Patterson C, Perrella MA, Endege WO, Yoshizumi M, Lee M, and Haber E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-α in cultured human vascular endothelial cells. J Clin Invest 98: 490-496, 1996.
26. Plate KH, Breier G, Millauer B, Ullrich A, and Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53: 5822-5827, 1993.
27. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overhosler J, Hooper A, Pytowski B, Witte L, Bohlen P, and Hicklin DJ. Anti-vascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209-5218, 1999.
28. Schuster LM, Haluska F, Fraker DL, and Elenitsas R. Skin: malignant melanoma. In: Clinical Oncology (2nd Ed.). New York: Churchill Livingstone, 2000, p. 1317-1350.
29. Shalaby FJ, Rossant TP, Yamaguchi M, Gertenstein X, Wu ML, Breitman, and Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66, 1995.
30. Shweiki D, Itin A, Soffer D, and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 359: 843-845, 1992.
31. Spriggs DR and Yates SW. Cancer chemotherapy: experiences with TNF administration in humans. In: Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, New York: Raven, 1992, p. 383-406.
32. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, and Shawver LK. Flk-1 as a target for tumor growth inhibition. Cancer Res 56: 3540-3545, 1996.
33. , Wojciak-Stothard B, Entwistle A, Garg R, and Ridley AJ. Regulation of TNF-α-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J Cell Physiol 176: 150-165, 1998.
34. Wong RK, Baldwin AL, and Heimark RL. Cadherin-5 redistribution at sites of TNF-α and IFN-γ-induced permeability in mesentric venules. Am J Physiol Heart Circ Physiol 276: H736-H748, 1999.